INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 800 participants.
Also called NCT07906275
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 800 participants
- Registry
-
NCT07906275
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07906275. Randomized; single masking; primary purpose treatment. Start 2026-12-15 (anticipated); primary completion 2030-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
- Acronym
- IMP-ACT
- Condition
- Stroke, Acute Ischemic
- Condition
- Medium Vessel Occlusion
- Intervention (Procedure)
- Mechanical Endovascular Thrombectomy
- Intervention (Drug)
- Intravenous Thrombolysis
- Intervention (Biological)
- Tenecteplase/Alteplase- depending upon availability at each treating centre
- Lead sponsor
- University of Calgary
- Collaborator
- The George Institute for Global Health, Australia
Record details
- Record id
cardio:ct-nct07906275- Content hash
7f26cbe651c86a5ec2e9495d665389ee71159c944ca6d2eb4c2a4b97f372cea5